Life Science Fundraising & Investment
24 March 2026 - Pre-day forums (Life Science Companies only), FIL (Feira Internacional de Lisboa)25-26 March 2026 - Main days, Lisbon Congress Centre, Lisbon, Portugalkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day Two - Western European Summer Time (WEST)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Formats
Day Two - Western European Summer Time (WEST)
search
Streams
Clear
Formats
Showing 1 of 1 Streams
Biotech Leaders Morning Keynote Plenary
09:00 - 09:05
LSX Welcome Address: Biotech Leaders
- Adam Griffiths - Portfolio Manager, LSX
09:05 - 09:35
State of Biotech Markets: A Forward-looking View
- Cody Powers - Partner, ZS Associates
09:35 - 10:30
Investment, Innovation, and Influence: Reimagining Europe’s Role in Global Life Sciences
- Sonia Hallen - Investment Manager, Gilde Healthcare
- Adam Schoen - Partner, Brown Rudnick
- Holger Kissel - SVP Corporate Strategy, BioNtech
- Giovanni Mariggi - Partner, Medicxi
Showing 3 of 3 Streams
Early Innovation & Technology Translation
Capital Markets & Investment Strategies
Market Opportunities & Commercialisation
11:30 - 12:10
Global Hotbeds of Innovation: Where Will the Next Breakthroughs Come From?
- Sascha Berger - Investment Director, NEOM
- Ester Sklarsky - Principal, Sound Bioventures
- Emilio Erazo-Fischer - Operating Partner, Asabys Partners
- Luka Nicin - VC Investor, Pace Ventures
12:10 - 12:50
From Lab to Launch: How to Turn Academic Research into a Viable Biotech
- Deborah Sterling - Director, Sterne Kessler
- Martin Svorc - Director, Neurology & Immunology, Fertility Business Development, Merck KGaA
- Laura Ferguson - Director, Platform Technologies Search and Evaluation, AstraZeneca
- Michel de Baar - Executive Director, Business Development, Europe, Merck
- Johan Juhlin - CEO, Mavatar
11:10 - 11:30
Partnering with Debiopharm
- Damian Ibanez - Associate Search & Evaluation Oncology, Debiopharm
11:30 - 12:10
The Current State of Biotech Investing: Where is the Smart Money Going in 2026?
- Hakan Goker - Managing Director, M Ventures
- Jamie Bignal - Director, HSBC Innovation Banking
- João Incio - General Partner, Biovance Capital
- Achim Plum - Managing Director, HTGF
- Joao Ribas - Venture Partner, Novo Holdings
12:10 - 12:50
Biotech’s Rising South: Mapping Investment and Innovation in Southern Europe
- Amanda Gett - Partner, Kurma Partners
- João Eurico Cabral da Fonseca - Dean, Lisbon School of Medicine, University of Lisbon
- Ricardo Henriques - Managing Partner & Co-founder, Biovance Capital
- Natalia Misciattelli - CEO, AAVantgarde Bio
- Antonio Herce - Director - Life Sciences, Inveready
11:10 - 11:30
Future-proofing Your Launch: Data and Strategies for What’s Next
The healthcare industry has always evolved, but the scale and pace of change have accelerated in recent years—with major shifts across policy, technology and the broader healthcare landscape. What do these changes mean for biopharma companies and how they bring products to market? How do they affect revenue potential, clinical program design and other critical launch preparations?
Join this session to:
- Hear the latest research and data on what drives launch success today
- Gain practical insights on how to prepare for future market dynamics
- Learn from an expert panel discussion exploring real-world examples and implications for launch strategy
- Mark Rayward-Smith - Principal, ZS
11:30 - 12:10
Future-proofing Your Launch: Data and Strategies for What’s Next Panel Discussion
The healthcare industry has always evolved, but the scale and pace of change have accelerated in recent years—with major shifts across policy, technology and the broader healthcare landscape. What do these changes mean for biopharma companies and how they bring products to market? How do they affect revenue potential, clinical program design and other critical launch preparations?
Join this session to:
- Hear the latest research and data on what drives launch success today
- Gain practical insights on how to prepare for future market dynamics
- Learn from an expert panel discussion exploring real-world examples and implications for launch strategy
- Mark Rayward-Smith - Principal, ZS
12:10 - 12:50
Early Commercial Strategy: Building Value from Day One
- Matthias Hess - SVP Head of Europe, SpringWorks Therapeutics
- Rasmus Just - Global Head, Business Development, M&A, Licensing, Search & Evaluation, ALK
- Elin Trampe - CEO, Dicot Pharma
- Jonas Båtelson - CEO, Curacell
- Khatereh Ahmadi - Venture Partner, XGEN Venture
Showing 3 of 3 Streams
Early Innovation & Technology Translation
Capital Markets & Investment Strategies
Market Opportunities & Commercialisation
14:00 - 14:50
Rare Diseases vs. Broad Indications: Where to Focus Early-Stage Innovation
- Lori Badura - Head of Global Partnering Rare Disease & Neuroscience, IPSEN
- Sten Sörensen - CEO, Cereno Scientific
- Linda McGoldrick - Independent International Director, Member of Council, Ministry of Science and Innovation for Portugal
- Gražina Mykolaitytė - CEO, VUGENE
14:50 - 15:40
Next-Gen Modalities: Beyond Antibodies and Small Molecules
- Christopher Church - Head of Technology Search & Evaluation, Biopharmaceuticals R&D, AstraZeneca
- Hiro Usuda - Scouting & Transaction Lead, Astellas
- Jonas Båtelson - CEO, Curacell
- Cristiana Pires - CEO, Asgard Tx
14:00 - 14:50
Navigating Biotech Financing: Balancing Private Resilience and Public Opportunities
- Søren Lemonius - Managing General Partner, Sunstone Life Science Ventures
- Fabian Scheugenpflug - Principal, Plug and Play
- Pierre Joffrin - Senior Associate, Syncona
- Daniel Forman - Partner, Lowenstein Sandler
14:50 - 15:40
Inside the Investor Mind: How Biotech VCs Are Making Decisions Today
- Tim Lohoff - Principal, Forbion
- Max Klement - Partner, Venture Investments, Novo Holdings
- Nuno Alves - Associate Director, Business Development, Astellas
- Claire Brown - Partner, Oxford Science Enterprises
- Georgina Askeland - Senior Investment Associate, Hadean Ventures
- Phil Masterson - Associate Director, Ventures, Cancer Research Horizons
14:00 - 14:50
Oncology’s Next Frontier: Future Opportunities in an Ever-Growing Market
- Sonal Patel - VP, Oncology Scientific Innovation, Johnson & Johnson Innovation
- Alan Rigby - CEO, Epitopea
- Ana Slipicevic - CEO, One-Carbon Therapeutics
- Carlos Buesa - CEO, Oryzon Genomics
14:50 - 15:40
Pricing & Market Access Strategy for Novel Modalities
- Francis Pang - SVP, Global Market Access & International Geographic Expansion, Orchard Therapeutics
- Ulf Staginnus - VP International Market Access & Pricing, Blueprint Medicines
- René Schüler - VP, Head of Market Access Europe, SpringWorks Therapeutics
Showing 1 of 1 Streams
Biotech Leaders Afternoon Keynote Plenary
16:20 - 17:00
Biotech’s Next Frontier: Unlocking the Future of Early-Stage Funding
- Roel Bulthuis - Managing Partner, Head of Investments, Syncona
- Arno de Wilde - Managing Director, EQT Life Sciences
- Josh Little - Senior Associate, M&A, A&O Shearman
- Tobias Horneman-Thielcke - Partner, Eir Ventures
- Hans T. Schambye - Chair of Dansk Biotek, CEO & President of Galecto, Galecto
- Megan McMellon - Senior Associate, Commercial IP, A&O Shearman
17:00 - 17:40
Strategic Pharma Business Development: M&A and Beyond
- Melanie Howard - Partner, Latham & Watkins
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear
Formats